DoE approach for development of localized controlled release microspheres of Vancomycin for treatment of septic arthritis

Future Journal of Pharmaceutical Sciences

Table 2 Different responses of Vancomycin HCl microspheres employed in Box–Behnken experimental design

Formulation code	Percentage yield (%)	Particle size (Y₁, µm)	Entrapment efficiency (Y₂, %)	Drug release (Y₃, %)
VMS 1	87.5 ± 0.12	18.26 ± 0.31	33.17 ± 0.32	68.04 ± 0.31
VMS 2	92 ± 0.20	12.92 ± 0.65	45.94 ± 0.12	74.10 ± 0.45
VMS 3	90 ± 0.40	4.44 ± 0.64	79.92 ± 0.42	88.02 ± 0.42
VMS 4	85.2 ± 0.31	5.02 ± 0.41	80.42 ± 0.44	84.03 ± 0.61
VMS 5	88.8 ± 0.12	10.23 ± 0.51	58.05 ± 0.51	80.29 ± 0.53
VMS 6	84.2 ± 0.32	14.20 ± 0.32	42.19 ± 0.23	74.30 ± 0.65
VMS 7	85 ± 0.4	6.29 ± 0.61	52.06 ± 0.11	82.02 ± 0.72
VMS 8	86.25 ± 0.51	20.28 ± 0.42	27.12 ± 0.61	69.50 ± 0.21
VMS 9	92.7 ± 0.26	11.50 ± 0.22	50.16 ± 0.32	76.02 ± 0.61
VMS 10	90.05 ± 0.42	15.09 ± 0.51	40.24 ± 0.61	72.32 ± 0.42
VMS 11	86.66 ± 0.61	8.26 ± 0.45	60.06 ± 0.51	78.31 ± 0.32
VMS 12	83.40 ± 0.51	7.89 ± 0.52	64.02 ± 0.21	81.3 ± 0.22